Cantor Fitzgerald Reaffirms “Hold” Rating for Allergan PLC. (AGN)
AGN has been the subject of several other research reports. UBS AG reiterated a buy rating and issued a $275.00 price objective on shares of Allergan PLC. in a research note on Monday, May 15th. Vetr upgraded shares of Allergan PLC. from a sell rating to a hold rating and set a $242.88 price objective for the company in a research note on Monday, June 26th. Wells Fargo & Company reiterated an outperform rating and issued a $280.00 price objective (up previously from $270.00) on shares of Allergan PLC. in a research note on Wednesday, August 9th. Goldman Sachs Group, Inc. (The) cut shares of Allergan PLC. from a buy rating to a neutral rating and set a $262.00 price objective for the company. in a research note on Wednesday, May 10th. Finally, Royal Bank Of Canada raised their price objective on shares of Allergan PLC. from $279.00 to $284.00 and gave the company an outperform rating in a research note on Wednesday, May 10th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and fifteen have given a buy rating to the company’s stock. The company has an average rating of Buy and a consensus price target of $275.49.
Allergan PLC. (NYSE AGN) opened at 229.48 on Tuesday. The firm has a market cap of $76.72 billion, a P/E ratio of 6.99 and a beta of 1.16. The firm has a 50 day moving average of $238.58 and a 200-day moving average of $238.02. Allergan PLC. has a 12 month low of $184.50 and a 12 month high of $256.80.
Allergan PLC. (NYSE:AGN) last issued its earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.95 by $0.07. The business had revenue of $4.01 billion for the quarter, compared to the consensus estimate of $3.95 billion. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The business’s quarterly revenue was up 8.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.35 earnings per share. On average, equities research analysts forecast that Allergan PLC. will post $16.27 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Cantor Fitzgerald Reaffirms “Hold” Rating for Allergan PLC. (AGN)” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://www.thecerbatgem.com/2017/09/01/cantor-fitzgerald-reaffirms-hold-rating-for-allergan-plc-agn.html.
The company also recently announced a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Friday, August 18th will be paid a $0.70 dividend. The ex-dividend date is Wednesday, August 16th. This represents a $2.80 annualized dividend and a dividend yield of 1.22%. Allergan PLC.’s dividend payout ratio (DPR) is presently 9.95%.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Howard Hughes Medical Institute purchased a new position in shares of Allergan PLC. during the second quarter valued at $103,000. Enterprise Financial Services Corp increased its position in shares of Allergan PLC. by 62.7% in the first quarter. Enterprise Financial Services Corp now owns 462 shares of the company’s stock valued at $110,000 after buying an additional 178 shares during the period. Jacobi Capital Management LLC increased its position in shares of Allergan PLC. by 4.9% in the first quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock valued at $112,000 after buying an additional 22 shares during the period. JNBA Financial Advisors increased its position in shares of Allergan PLC. by 2.5% in the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock valued at $116,000 after buying an additional 12 shares during the period. Finally, Massey Quick & Co. LLC boosted its stake in Allergan PLC. by 334.8% in the second quarter. Massey Quick & Co. LLC now owns 500 shares of the company’s stock valued at $122,000 after buying an additional 385 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.